trending Market Intelligence /marketintelligence/en/news-insights/trending/At0vFFEJMGJsOZ7jTspfjQ2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Immunotec fiscal Q2 profit climbs YOY

Blog

ESG hits the mainstream for European private equity sponsors

Blog

What’s the Bottom Line: Credit Impact of COVID-19 on US Municipals

Blog

Banking Essentials Newsletter - February Edition, Part 2

Podcast

Episode 3: Transformation of Customer Experience in 2020


Immunotec fiscal Q2 profit climbs YOY

Immunotec Inc. said its normalized net income for the fiscal second quarter ended April 30 came to C$633,090, a gain from C$267,070 in the prior-year period.

Normalized net income excludes unusual gains or losses on a pre- and after-tax basis.

The normalized profit margin rose to 2.5% from 1.3% in the year-earlier period.

Total revenue climbed 28.1% on an annual basis to C$25.6 million from C$20.0 million, and total operating expenses climbed 26.9% on an annual basis to C$23.8 million from C$18.7 million.

Reported net income grew 61.9% year over year to C$559,280, or 1 cents per share, from C$345,510, or 0 cents per share.